S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ELYM Eliem Therapeutics Inc

4.10

0.71 (20.94%)

27 Apr 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Eliem Therapeutics (NASDAQ:ELYM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Eliem Therapeutics Charts.

Eliem Therapeutics (NASDAQ:ELYM)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Eliem Therapeutics Charts.

Eliem Therapeutics Inc News

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
Friday 12 April 2024 (2 weeks ago) • PR Newswire (US)

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Thursday 11 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 15 November 2023 (5 months ago) • Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Tuesday 14 November 2023 (5 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 11 August 2023 (9 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 20 July 2023 (9 months ago) • Edgar (US Regulatory)

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
Thursday 20 July 2023 (9 months ago) • GlobeNewswire Inc.

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
Friday 12 May 2023 (12 months ago) • GlobeNewswire Inc.

More Eliem Therapeutics Inc News Articles

Australia And New Zealan...

Sterling vs AUD

Westpac Banking

Verizon Communications

Australian SE All Ordina...

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions